No connection

Search Results

INM vs PRFX

INM
InMed Pharmaceuticals Inc.
BEARISH
Price
$0.72
Market Cap
$2.4M
Sector
Healthcare
AI Confidence
95%
PRFX
PRF Technologies Ltd.
BEARISH
Price
$2.73
Market Cap
$2.3M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
INM
--
PRFX
--
Forward P/E
INM
-0.11
PRFX
-0.23
P/B Ratio
INM
0.21
PRFX
0.27
P/S Ratio
INM
0.53
PRFX
135.62
EV/EBITDA
INM
0.57
PRFX
0.25

Profitability

Gross Margin
INM
29.73%
PRFX
0.0%
Operating Margin
INM
-258.57%
PRFX
-16200.0%
Profit Margin
INM
-170.07%
PRFX
0.0%
ROE
INM
-97.2%
PRFX
-90.37%
ROA
INM
-49.77%
PRFX
-38.75%

Growth

Revenue Growth
INM
-26.2%
PRFX
--
Earnings Growth
INM
--
PRFX
--

Financial Health

Debt/Equity
INM
0.06
PRFX
0.0
Current Ratio
INM
5.94
PRFX
1.78
Quick Ratio
INM
4.85
PRFX
1.75

Dividends

Dividend Yield
INM
--
PRFX
--
Payout Ratio
INM
0.0%
PRFX
0.0%

AI Verdict

INM BEARISH

The company exhibits critical financial distress, highlighted by a Piotroski F-Score of 1/9, indicating severe weakness across nearly all fundamental health dimensions. While the current ratio is high (5.94), this is offset by a catastrophic profit margin of -170.07% and declining year-over-year revenue growth of -26.20%. The stock is in a clear long-term death spiral, with a 5-year price change of -100% and a technical trend score of 0/100. Without a pivot to profitability or a significant capital infusion, the business model appears unsustainable.

Strengths
Very low Debt/Equity ratio (0.06) indicating minimal long-term debt burden
Strong short-term liquidity with a Current Ratio of 5.94
Positive Gross Margin (29.73%) suggesting the core product has some inherent value
Risks
Critical financial health as evidenced by a 1/9 Piotroski F-Score
Severe operational inefficiency with an Operating Margin of -258.57%
Negative revenue growth (-26.20% YoY) indicating shrinking market share or demand
PRFX BEARISH

PRFX exhibits severe financial distress, characterized by a Piotroski F-Score of 4/9, which barely places it in the 'stable' category despite catastrophic operating margins of -16,200%. The absence of an Altman Z-Score and Graham Number reflects a lack of positive earnings and stable valuation foundations. With a Price-to-Sales ratio of 135.62 and a 5-year price collapse of 99.7%, the company appears to be a speculative shell with virtually no meaningful revenue generation. While the current ratio of 1.78 provides a temporary liquidity cushion, the fundamental business model is currently non-viable.

Strengths
Zero debt-to-equity ratio
Current ratio of 1.78 indicates short-term liquidity
Recent Q/Q EPS growth showing improvement from deep negatives
Risks
Extreme operating margin of -16,200% indicating massive inefficiency
Absurdly high Price-to-Sales ratio (135.62) suggesting negligible revenue
Total collapse of long-term shareholder value (-99.7% over 5 years)

Compare Another Pair

INM vs PRFX: Head-to-Head Comparison

This page compares InMed Pharmaceuticals Inc. (INM) and PRF Technologies Ltd. (PRFX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile